Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other solid neoplasm 1Breast 1

Conditions

Neoplasms 17Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasm Metastasis 6Prostatic Neoplasms 5Melanoma 5Lung Neoplasms 5Solid Tumor 3Pain, Postoperative 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Gastrointestinal Stromal Tumors 3Colorectal Neoplasms 3Anxiety Disorders 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Pain 2Glioma 2Colonic Neoplasms 2Choledocholithiasis 2Choledochal Cyst 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1

Interventions

Rituximab 344Cyclophosphamide 317fludarabine phosphate 142Etoposide 139Peripheral Blood Stem Cell Transplantation 124fludarabine 112Filgrastim 112Mycophenolic Acid 98Melphalan 98Whole-Body Irradiation 90Vincristine 90Busulfan 87Cytarabine 85Doxorubicin 79Cyclosporine 76Tacrolimus 75Radiotherapy 75Prednisone 73Bendamustine Hydrochloride 72Granulocyte Colony-Stimulating Factor 66Methotrexate 65Antilymphocyte Serum 56Carmustine 54Dexamethasone 50Gemcitabine 48Lenalidomide 46Bortezomib 43venetoclax 41ibritumomab tiuxetan 37obinutuzumab 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × Midazolam × Clear all
NCT01296555 2024-07-31

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Genentech, Inc.

Phase 1 Terminated
674 enrolled 55 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

NCT01026415 2014-12-18

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Seagen Inc.

Phase 1 Completed
73 enrolled
Lymphoid

Carcinoma, Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡